22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Macron's China visit strengthens ties, boosts cooperation on global issues
- CPC issues revised regulations on its working bodies
- Melodic harmony under gingko tree
- Media tour explores Xiamen's tech surge and smart manufacturing
- Discover Xiamen with beauty of ecological governance
- Conference aimed at strengthening global organ donations opens in Guangzhou
